{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.759","value":"4.47"},{"groupId":"OG001","spread":"4.83","value":"10.3"},{"groupId":"OG002","spread":"0.318","value":"4.96"},{"groupId":"OG003","spread":"2.68","value":"9.68"},{"groupId":"OG004","spread":"1.86","value":"5.95"},{"groupId":"OG005","spread":"6.18","value":"7.59"},{"groupId":"OG006","spread":"11.1","value":"11.5"},{"groupId":"OG007","spread":"2.52","value":"7.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.25","value":"3.82"},{"groupId":"OG001","spread":"8.57","value":"10.1"},{"groupId":"OG002","spread":"0.540","value":"8.29"},{"groupId":"OG003","spread":"1.09","value":"7.62"},{"groupId":"OG004","spread":"3.13","value":"6.71"},{"groupId":"OG005","spread":"4.29","value":"7.48"},{"groupId":"OG006","spread":"3.43","value":"9.18"},{"groupId":"OG007","spread":"1.70","value":"6.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG000","spread":"NA","value":"4.71"},{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG003","spread":"NA","value":"7.84"},{"groupId":"OG004","spread":"1.29","value":"5.51"},{"groupId":"OG005","spread":"3.16","value":"6.60"},{"groupId":"OG006","spread":"0.0252","value":"7.91"},{"groupId":"OG007","spread":"2.03","value":"7.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.854","value":"3.83"},{"groupId":"OG001","spread":"8.54","value":"9.62"},{"groupId":"OG002","spread":"1.38","value":"7.30"},{"groupId":"OG003","spread":"1.34","value":"8.52"},{"groupId":"OG004","spread":"4.57","value":"8.11"},{"groupId":"OG005","spread":"3.64","value":"8.21"},{"groupId":"OG006","spread":"5.26","value":"9.46"},{"groupId":"OG007","spread":"2.27","value":"6.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"66"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG005","spread":"NA","value":"335"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"description":"Vss for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Volume of Distribution at Steady State (Vss) for ADCT-402","type":"SECONDARY","unitOfMeasure":"liters"}